Skip to content
Home/Companies/Biotech/Concert Bio
Concert Bio

Concert Bio

Biotech·United Kingdom·Active·4yr hold
Entry
2022
Hold
4yr
Status
Active

Who owns Concert Bio?

Concert Bio is a British Biotech company, currently owned by Nucleus Capital since 2022.

Hand-verified · updated 2026-07-03

Open JSON · CC-BY
Nucleus Capital
Investor
Nucleus Capital
Nucleus Capital I · 2021 · VC

Key facts

HQUnited Kingdom
SectorBiotech
StatusActive
Websitewww.concert.bio

More from Nucleus Capital I

Other portfolio companies in the same fund.

atmio
Active
ClimateTechGermany· 2023
Biographica
Biographica
Active
BiotechUK· 2023
Biomia
Biomia
Active
BiotechDenmark· 2023
Brineworks
Brineworks
Active
ClimateTechNetherlands· 2023
Endolith
Endolith
Active
IndustrialsUS· 2023
Farmless
Farmless
Active
FoodTechNetherlands· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Concert Bio?

Concert Bio is currently owned by Nucleus Capital, through Nucleus Capital I, since 2022.

When did Nucleus Capital acquire Concert Bio?

Nucleus Capital acquired Concert Bio in 2022.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue